A Phase 3 interventional study of Rozanolixizumab in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Completed at 69 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing rozanolixizumab in Myasthenia Gravis — 2 open to participants now, 4 under way, 3 of them phase 3. rozanolixizumab · Myasthenia Gravis.
Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 7 in phase 3, and was the 4th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →2 of the 10 studies testing rozanolixizumab in Myasthenia Gravis are open now, in 9 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, China and 6 more countries
Ages 18+
By country, each count listing its studies:
rozanolixizumab: first FDA approval 2023 (RYSTIGGO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 8 · Phase 4 1
First in 2017; this study’s year is marked. 1 started in 2021.
This study's enrollment of 165 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 67 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
18 studies in Myasthenia Gravis by UCB S.A.: 5 open now, 7 under way, 5 of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 18 studies in Myasthenia Gravis by UCB S.A., this one is the 4th largest by enrollment, is the only one that started in 2021, is one of 12 in phase 3, and was the 7th registered.
UCB S.A.’s Myasthenia Gravis studies by the year they started, since 2017.
2 of the studies testing rozanolixizumab in Myasthenia Gravis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06540144Phase 3UCB Biopharma SRLAn Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis | 2027-10-05 |
| NCT07246564UCB Biopharma SRLPhase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, from their registry updates:
Among UCB S.A.’s 18 in Myasthenia Gravis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study participant must meet one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants randomized/assigned to dosage regimen 1 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
Drug: Rozanolixizumab
Study participants randomized/assigned to dosage regimen 2 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
Drug: Rozanolixizumab
Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Also known as: UCB7665
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which did not necessarily had a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAE was defined as any event that was not present prior to first dose of investigational medicinal product (IMP), or any unresolved event already present that worsened in intensity following treatment, up to 8 weeks after end of Treatment Period or after last dose of IMP in participants who discontinued study or IMP.
Time frame: From Baseline (Day 1) to End of Study (up to 34 months)
Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (IMP)
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. AEs leading to permanent withdrawal of study medication.
Time frame: From Baseline (Day 1) to End of Study (up to 34 months)
Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score Within One Treatment Cycle (Cycle 1, 2, and 3)
The MG-ADL is an 8-item PRO instrument developed on basis of QMG. The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0= no symptoms or impaired performance and 3= most severe symptoms or impaired performance. The total score ranges from 0 to 24, with higher score indicating more disability. A positive change in score indicates worsening and negative change indicates improvement. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.
Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Change From Baseline (Day 1) to Day 43 in Quantitative Myasthenia Gravis (QMG) Score Within One Treatment Cycle (Cycle 1, 2, and 3)
The QMG is a validated assessment and the scale tested 13 items, including ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3) and the score ranges from 0 to 39, with lower scores indicating lower disease activity. A positive change in the score indicates worsening and a negative change indicates improvement. For the analyses done by study cycle, Baseline values were the last available values prior to or on the same date (and same time if time was collected for the individual assessment) of first administration of IMP at each cycle (ie, Baseline \[Day 1\]) value for that cycle.
Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Composite (MG-C) Score Within One Treatment Cycle (Cycle 1, 2, and 3)
MG-C scale consists of 10 items which included ptosis (score range=0 to 3), double vision on lateral gaze left/right/both (score range=0 to 4), eye closure (score range=0 to 2), talking (score range=0 to 6), chewing (score range=0 to 6), swallowing (score range=0 to 6), breathing (score range=0 to 9), neck flexion or extension (score range=0 to 4), shoulder abduction (score range=0 to 5) and hip flexion (score range= 0 to 5), lower scores= lower disease activity. Total MG-C score obtained by summing responses to each individual item and score ranges from 0 - 50, (lower scores indicating lower disease activity). Positive change = worsening, and negative change = improvement. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.
Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Muscle Weakness Fatigability' Score Within One Treatment Cycle (Cycle 1, 2, and 3)
The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular symptoms (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Study participants had to choose response option that best described severity of ocular, bulbar, and respiratory symptoms over past 7 days using a 4-point Likert scale ("none" to "severe") and frequency of experiencing physical fatigue and muscle weakness fatigability over past 7 days using a 5-point Likert scale (1="none of the time" - 5= "all of the time"), for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicates more severe symptoms. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.
Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Change From Baseline (Day 1) to Day 43 in MG Symptoms PRO 'Physical Fatigue' Score Within One Treatment Cycle (Cycle 1, 2, and 3)
The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Study participants had to choose response option based on frequency of experiencing physical fatigue (19-33) over past 7 days using a 5-point Likert scale (1="none of time" - 5="all of time") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicated severe symptoms.
Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Change From Baseline (Day 1) to Day 43 in MG Symptoms PRO 'Bulbar Muscle Weakness' Score Within One Treatment Cycle (Cycle 1, 2, and 3)
The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Bulbar symptoms are now recognised as bulbar muscle weakness. Study participants were asked to choose response option that best described severity of bulbar muscle weakness (6-15) symptoms over past 7 days using a 4-point Likert scale (1="none" to 4="severe") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicated severe symptoms.
Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
MG-ADL Responder Rate (>=2.0-point Improvement From Baseline [Day 1]) Within One Treatment Cycle (Cycle 1, 2, and 3 [Day 43])
The MG-ADL is an 8-item PRO instrument developed on the basis of the Quantitative Myasthenia Gravis (QMG). The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A MG-ADL responder was defined as achieving at least 2.0-point improvement (decrease) in the MG-ADL score from Baseline.
Time frame: Day 43 of Cycle 1, 2, and 3
Time to MG-ADL Response (>=2.0-point Improvement From Baseline [Day 1]) Within One Treatment Cycle (Cycle 1, 2, and 3)
Time to achieve MG-ADL response, defined as at least 2.0-point improvement from Baseline. Time to first MG-ADL response (in days) by study cycle was defined as date of first MG-ADL Response within study cycle - date of MG-ADL Baseline within study cycle + 1.
Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Time Between Consecutive Treatment Cycles
Time between consecutive treatment cycles: Study participants were assessed for MG worsening prior to repeated cycles. In case of symptom worsening (eg, an increase of 2.0 points on MG-ADL or 3.0 points on QMG scale) between assessments, resulted additional treatment, study participants undergone another 6-week treatment cycle followed by an Observation Period, based on Investigator's discretion. Time between treatment cycles was calculated as: date of first sc infusion in consecutive cycle - date of last sc infusion before new cycle + 1 (or date of censoring - date of last sc infusion before potential new cycle + 1).
Time frame: From end of the 6-week treatment cycle (Day 43) to the next 6-week treatment cycle (Day 1), assessed up to 2.5 years
The study started to enroll participants in February 2021 and concluded in January 2024. Participant Flow refers to Full Analysis Set (FAS).
| Milestone | Enrolled, But Not Treated | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|---|
| Started | 8 | 80 | 77 |
| Completed | 3 | 15 | 16 |
| Not completed | 5 | 65 | 61 |
| Withdrew: Adverse event | 1 | 12 | 14 |
| Withdrew: Lack of efficacy | 1 | 3 | 6 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 17 | 9 |
| Withdrew: Last treatment per sponsor lplv timelines | 0 | 12 | 6 |
| Withdrew: Participant withdrawn after drug approved by fda | 0 | 0 | 1 |
| Withdrew: Pi withdrew the patients from the study | 0 | 0 | 1 |
| Withdrew: Withdraw per sponsor's directive | 0 | 1 | 0 |
| Withdrew: Withdrawal due to prohibited treatment | 0 | 0 | 1 |
| Withdrew: Use of rescue medication | 0 | 0 | 1 |
| Withdrew: Last treatment per sponsor | 0 | 0 | 2 |
| Withdrew: Rescue medication | 0 | 0 | 1 |
| Withdrew: Participant want to start a family | 0 | 0 | 1 |
| Withdrew: Withdraw based on sponsor decision | 0 | 0 | 1 |
| Withdrew: Participant screened for mg0020 | 0 | 2 | 3 |
| Withdrew: Patient withdrawn due to inappropriate behavior | 0 | 1 | 0 |
| Withdrew: Subject performed peot, not a completed subject | 0 | 1 | 0 |
| Withdrew: Participant to be screened for mg0020 study | 0 | 4 | 5 |
| Withdrew: End of study | 0 | 2 | 1 |
| Withdrew: Wish to continue study imp in patient programme | 0 | 1 | 0 |
| Withdrew: Participant received rescue medication | 0 | 1 | 0 |
| Withdrew: Patient withdrawn; lack of imp shipments | 0 | 2 | 1 |
| Withdrew: Last treatment per lplv, screened for mg0020 | 0 | 2 | 2 |
| Withdrew: Discontinued due to chronic heart failure | 0 | 0 | 1 |
| Withdrew: Last treatment per sponsor lplv timelines- japan | 0 | 3 | 3 |
| Withdrew: Enrollment cup | 0 | 0 | 1 |
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which did not necessarily had a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAE was defined as any event that was not present prior to first dose of investigational medicinal product (IMP), or any unresolved event already present that worsened in intensity following treatment, up to 8 weeks after end of Treatment Period or after last dose of IMP in participants who discontinued study or IMP.
| percentage of participants | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 78.4 | 94.1 |
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. AEs leading to permanent withdrawal of study medication.
| percentage of participants | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (IMP) | 9.8 | 16.7 |
The MG-ADL is an 8-item PRO instrument developed on basis of QMG. The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0= no symptoms or impaired performance and 3= most severe symptoms or impaired performance. The total score ranges from 0 to 24, with higher score indicating more disability. A positive change in score indicates worsening and negative change indicates improvement. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.
| score on a scale | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Cycle 1: Treatment (Day 43) | -3.7 ± 3.5 | -3.1 ± 2.9 |
| Cycle 2: Treatment (Day 43) | -2.9 ± 3.1 | -3.8 ± 3.9 |
| Cycle 3: Treatment (Day 43) | -3.3 ± 2.7 | -3.2 ± 3.3 |
The QMG is a validated assessment and the scale tested 13 items, including ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3) and the score ranges from 0 to 39, with lower scores indicating lower disease activity. A positive change in the score indicates worsening and a negative change indicates improvement. For the analyses done by study cycle, Baseline values were the last available values prior to or on the same date (and same time if time was collected for the individual assessment) of first administration of IMP at each cycle (ie, Baseline \[Day 1\]) value for that cycle.
| score on a scale | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Cycle 1: Treatment (Day 43) | -4.5 ± 5.0 | -4.1 ± 4.2 |
| Cycle 2: Treatment (Day 43) | -3.9 ± 4.1 | -4.9 ± 5.5 |
| Cycle 3: Treatment (Day 43) | -5.1 ± 4.8 | -4.2 ± 4.4 |
MG-C scale consists of 10 items which included ptosis (score range=0 to 3), double vision on lateral gaze left/right/both (score range=0 to 4), eye closure (score range=0 to 2), talking (score range=0 to 6), chewing (score range=0 to 6), swallowing (score range=0 to 6), breathing (score range=0 to 9), neck flexion or extension (score range=0 to 4), shoulder abduction (score range=0 to 5) and hip flexion (score range= 0 to 5), lower scores= lower disease activity. Total MG-C score obtained by summing responses to each individual item and score ranges from 0 - 50, (lower scores indicating lower disease activity). Positive change = worsening, and negative change = improvement. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.
| score on a scale | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Cycle 1: Treatment (Day 43) | -7.6 ± 7.3 | -4.7 ± 5.7 |
| Cycle 2: Treatment (Day 43) | -5.7 ± 5.4 | -7.5 ± 7.0 |
| Cycle 3: Treatment (Day 43) | -6.8 ± 5.9 | -6.1 ± 7.2 |
The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular symptoms (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Study participants had to choose response option that best described severity of ocular, bulbar, and respiratory symptoms over past 7 days using a 4-point Likert scale ("none" to "severe") and frequency of experiencing physical fatigue and muscle weakness fatigability over past 7 days using a 5-point Likert scale (1="none of the time" - 5= "all of the time"), for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicates more severe symptoms. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.
| score on a scale | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Cycle 1: Treatment (Day 43) | -17.6 ± 21.0 | -14.6 ± 17.2 |
| Cycle 2: Treatment (Day 43) | -13.2 ± 19.2 | -19.2 ± 21.6 |
| Cycle 3: Treatment (Day 43) | -12.8 ± 14.4 | -15.4 ± 17.7 |
The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Study participants had to choose response option based on frequency of experiencing physical fatigue (19-33) over past 7 days using a 5-point Likert scale (1="none of time" - 5="all of time") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicated severe symptoms.
| score on a scale | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Cycle 1: Treatment (Day 43) | -16.5 ± 18.6 | -14.8 ± 18.5 |
| Cycle 2: Treatment (Day 43) | -13.6 ± 21.6 | -16.0 ± 18.2 |
| Cycle 3: Treatment (Day 43) | -15.3 ± 16.9 | -15.0 ± 18.4 |
The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Bulbar symptoms are now recognised as bulbar muscle weakness. Study participants were asked to choose response option that best described severity of bulbar muscle weakness (6-15) symptoms over past 7 days using a 4-point Likert scale (1="none" to 4="severe") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicated severe symptoms.
| score on a scale | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Cycle 1: Treatment (Day 43) | -13.4 ± 19.8 | -11.6 ± 16.2 |
| Cycle 2: Treatment (Day 43) | -10.4 ± 16.2 | -15.5 ± 18.1 |
| Cycle 3: Treatment (Day 43) | -14.0 ± 16.8 | -13.0 ± 17.9 |
The MG-ADL is an 8-item PRO instrument developed on the basis of the Quantitative Myasthenia Gravis (QMG). The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A MG-ADL responder was defined as achieving at least 2.0-point improvement (decrease) in the MG-ADL score from Baseline.
| percentage of participants | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Cycle 1: Treatment (Day 43) | 74.3 | 63.6 |
| Cycle 2: Treatment (Day 43) | 62.5 | 67.7 |
| Cycle 3: Treatment (Day 43) | 73.2 | 67.2 |
Time to achieve MG-ADL response, defined as at least 2.0-point improvement from Baseline. Time to first MG-ADL response (in days) by study cycle was defined as date of first MG-ADL Response within study cycle - date of MG-ADL Baseline within study cycle + 1.
| days | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Cycle 1 | 9.00 (8.00 to 15.00) | 22.00 (15.00 to 36.00) |
| Cycle 2 | 15.00 (10.00 to 17.00) | 15.00 (9.00 to 22.00) |
| Cycle 3 | 15.00 (9.00 to 15.00) | 15.00 (9.00 to 17.00) |
Time between consecutive treatment cycles: Study participants were assessed for MG worsening prior to repeated cycles. In case of symptom worsening (eg, an increase of 2.0 points on MG-ADL or 3.0 points on QMG scale) between assessments, resulted additional treatment, study participants undergone another 6-week treatment cycle followed by an Observation Period, based on Investigator's discretion. Time between treatment cycles was calculated as: date of first sc infusion in consecutive cycle - date of last sc infusion before new cycle + 1 (or date of censoring - date of last sc infusion before potential new cycle + 1).
| days | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Between Cycle 1 and Cycle 2 | 64.0 (9 to 883) | 51.0 (2 to 856) |
| Between Cycle 2 and Cycle 3 | 58.0 (1 to 631) | 50.0 (15 to 575) |
| Between Cycle 3 and Cycle 4 | 42.5 (27 to 399) | 43.0 (5 to 194) |
| Between Cycle 4 and Cycle 5 | 43.0 (9 to 181) | 43.0 (17 to 242) |
| Between Cycle 5 and Cycle 6 | 44.0 (22 to 192) | 43.0 (15 to 175) |
| Between Cycle 6 and Cycle 7 | 36.0 (8 to 348) | 43.0 (7 to 106) |
| Between Cycle 7 and Cycle 8 | 37.0 (22 to 87) | 37.0 (6 to 84) |
| Between Cycle 8 and Cycle 9 | 36.0 (8 to 120) | 36.0 (7.0 to 134) |
| Between Cycle 9 and Cycle 10 | 29.0 (7 to 97) | 29.0 (8 to 72) |
| Between Cycle 10 and Cycle 11 | 29.0 (8 to 64) | 29.0 (8 to 99) |
| Between Cycle 11 and Cycle 12 | 23.0 (8 to 52) | 22.0 (7 to 37) |
| Between Cycle 12 and Cycle 13 | 22.0 (6 to 36) | 22.0 (7 to 38) |
| Between Cycle 13 and Cycle 14 | 29.0 (22 to 35) | 16.0 (8 to 65) |
| Between Cycle 14 and Cycle 15 | 29.0 (29 to 64) | 9.0 (8 to 16) |
| Between Cycle 15 and Cycle 16 | 23.0 (8 to 29) | 26.5 (9 to 44) |
| Between Cycle 16 and Cycle 17 | 29.0 (29 to 29) | — |
| Between Cycle 17 and Cycle 18 | 8.0 (8 to 8) | — |
Collected over Enrolled, but not treated: From Screening until End of Study (up to 34 months); Randomized participants: From Baseline (Day 1) until End of Study (up to 34 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enrolled, But Not Treated | 1/8 (12.5%) | 3/8 (37.5%) | 5/8 (62.5%) |
| Rozanolixizumab ~7 mg/kg | 1/102 (1%) | 16/102 (15.7%) | 67/102 (65.7%) |
| Rozanolixizumab ~10 mg/kg | 3/102 (2.9%) | 31/102 (30.4%) | 78/102 (76.5%) |
| Event | Enrolled, But Not Treated | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|---|
| Cardiac failureCardiac disorders | 1/8 | 0/102 | 1/102 |
| Myocardial infarctionCardiac disorders | 1/8 | 0/102 | 1/102 |
| Myasthenia gravisNervous system disorders | 1/8 | 5/102 | 11/102 |
| Myasthenia gravis crisisNervous system disorders | 1/8 | 0/102 | 4/102 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/8 | 0/102 | 0/102 |
| COVID-19Infections and infestations | 0/8 | 1/102 | 2/102 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/8 | 0/102 | 1/102 |
| Angina unstableCardiac disorders | 0/8 | 0/102 | 1/102 |
| Atrial fibrillationCardiac disorders | 0/8 | 0/102 | 1/102 |
| Adrenal disorderEndocrine disorders | 0/8 | 1/102 | 0/102 |
| Event | Enrolled, But Not Treated | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|---|
| HeadacheNervous system disorders | 0/8 | 36/102 | 46/102 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 20/102 | 28/102 |
| COVID-19Infections and infestations | 1/8 | 15/102 | 24/102 |
| PyrexiaGeneral disorders | 0/8 | 9/102 | 19/102 |
| NauseaGastrointestinal disorders | 0/8 | 9/102 | 18/102 |
| Blood immunoglobulin G decreasedInvestigations | 0/8 | 6/102 | 15/102 |
| NasopharyngitisInfections and infestations | 1/8 | 10/102 | 11/102 |
| Urinary tract infectionInfections and infestations | 1/8 | 6/102 | 2/102 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/8 | 3/102 | 6/102 |
| Hepatic painGeneral disorders | 1/8 | 0/102 | 0/102 |
Baseline characteristics refers to the Full Analysis set (FAS) which consisted of all enrolled study participants who were randomized in this study or in MG0004.
| Age, Continuous(years) | Enrolled, But Not Treated | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg | Total |
|---|---|---|---|---|
| Mean | 59.6 ± 17.6 | 52.5 ± 15.7 | 52.2 ± 17.0 | 52.7 ± 16.4 |
| Age, Customized(Participants) | Enrolled, But Not Treated | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg | Total |
|---|---|---|---|---|
| 18 to <65 years | 5 | 61 | 57 | 123 |
| 65 to <85 years | 2 | 19 | 19 | 40 |
| >=85 years | 1 | 0 | 1 | 2 |
| Sex: Female, Male(Participants) | Enrolled, But Not Treated | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg | Total |
|---|---|---|---|---|
| Female | 3 | 45 | 48 | 96 |
| Male | 5 | 35 | 29 | 69 |
| Race/Ethnicity, Customized(Participants) | Enrolled, But Not Treated | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg | Total |
|---|---|---|---|---|
| American Indian/Alaskan native | 0 | 0 | 0 | 0 |
| Asian | 0 | 8 | 8 | 16 |
| Black | 3 | 1 | 0 | 4 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 1 | 1 |
| White | 4 | 54 | 54 | 112 |
| Other/mixed | 0 | 0 | 0 | 0 |
| Missing | 1 | 17 | 14 | 32 |
| Race/Ethnicity, Customized(Participants) | Enrolled, But Not Treated | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 4 | 10 |
| Not Hispanic or Latino | 3 | 63 | 60 | 126 |
| Missing | 1 | 15 | 13 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Feb 2021 to primary completion in Jan 2024, 35 months.
Results were first posted in Apr 2025, 1 year 2 months after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 35 months is above that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rozanolixizumab